Annexon, Inc.

Deltagen, Inc.

University of California

Michael W Leviten

Arnon Rosenthal

Alan S Verkman

Ted A Yednock

Sethu Sankaranarayanan

The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.

Anti-complement factor C1q Fab fragments and uses thereof

The present invention provides anti-C1q antibodies and methods of using the same.

Anti-complement factor C1Q antibodies and uses thereof

Anti-complement factor C1q antibodies and uses thereof

The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.

Humanized anti-complement factor C1Q antibodies

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a HSPC150-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

HSPC150-like gene disruptions, compositions and methods related thereto

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a ubiquitin-specific protease 16 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

Growing community of inventors

Palo Alto, CA, United States of America

Michael W Leviten